- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Life Science & Biotech
Cook Group acquires local biotech company
April 9, 2012
IBJ StaffBloomington-based medical device maker Cook Group has acquired General BioTechnology LLC, an Indianapolis biotech company
with about 20 employees, Cook Group announced Monday.
MoreNew Lilly drug has small sales potential
April 9, 2012
J.K. WallEli Lilly and Co.’s newest drug is a boon for Alzheimer’s research but is likely to bring the Indianapolis drugmaker
less than $100 million in annual sales—at least initially, according to one of the few analysts to make a forecast.
MoreBiomet offers to acquire DePuy trauma biz for $280M
April 3, 2012
IBJ Staff and Bloomberg NewsWarsaw-based Biomet, which designs and manufactures orthopedic products for surgical and non-surgical uses, said the deal
would greatly expand its sports, extremities and trauma business.
MoreRoche's downsizing to claim about 80 local IT workers
March 29, 2012
IBJ StaffRoche Diagnostics Corp. plans to eliminate about 80 information technology jobs at its Indianapolis-area campus over the next
two years, the company said Thursday morning.
MoreDevice maker Biomet paying $22.7M to settle bribery case
March 26, 2012
Associated PressIndiana-based Biomet Inc. has agreed to pay $22.7 million to settle U.S. criminal and civil allegations that it bribed government-employed
doctors in Argentina, Brazil and China for eight years to win business with hospitals.
MoreQ&A
March 26, 2012
J.K. WallTino Pereira, CEO of Canada-based Iotron Industries, discussed the electron-beam facility his company opened
March 15 in Columbia City, which lies halfway between Fort Wayne and Warsaw in northern Indiana. Iotron already helps some
of the orthopedic implant makers in Warsaw alter the strength, flexibility or surface conditions of the materials in the joint
replacements they make. That makes its services important in research and development for new products.
MoreLilly receives Europe's OK for new Byetta use
March 23, 2012
IBJ Staff and Associated Press, Associated PressEuropean regulators have approved an expanded use for the diabetes treatment Byetta, developed by Eli Lilly and Co. and Amylin
Pharmaceuticals Inc. The FDA approved the same expanded use last fall.
MoreLife sciences firm plans to expand, add 46 jobs
March 15, 2012
Noblesville-based Helmer Inc. said it will invest $10.6 million to build a new manufacturing and headquarters facility at
the Saxony Corporate Campus near Interstate 69. It plans to add the jobs by 2014.
MoreEndocyte pulls trigger on European drug submission
March 13, 2012
J.K. WallEndocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after
the European Commission granted it orphan drug status.
MoreAIT Labs exec succeeding founder Evans as CEO
March 2, 2012
IBJ StaffThe promotions of several executives follow the Indianapolis-based clinical testing company's announcement in January that
it was cutting jobs and restructuring its business.
MoreCityWay designed to integrate retail, housing, hotel, YMCA
February 25, 2012
Marc D. AllanArchitects were told to push the envelope and integrate. Be mindful of where you are in the city and integrate well.
MoreEDITORIAL: BioCrossroads an example of vision at work
February 18, 2012
IBJ StaffWe hate to think what Indiana’s economic future might be if no one had made a point of putting the state’s life
sciences assets to work in a coordinated, strategic way.
MoreBioCrossroads has stoked state's life sciences industry, but challenges remain
February 11, 2012
J.K. WallIn the 10 years BioCrossroads has been promoting life sciences in Indiana, the effort has netted more than 330 new companies,
an infusion of more than $330 million in venture capital, a tripling of exports, and a growing number of mentions in national
reports on life sciences.
MoreHealth care VC hits new Indiana low in 2011
February 6, 2012
J.K. WallIndiana companies landed just $14.1 million in venture funding last year, the lowest amount of capital flowing to the
state’s health care sector since BioEnterprises began tracking such deals in 2005.
MoreDow Agro posts record fourth quarter profit
February 2, 2012
IBJ Staff and Associated PressThe Indianapolis-based unit of Dow Chemical Co. saw earnings grow to $142 million, a fourth-quarter record and double the
$72 million reported for the 2010 period.
MoreLilly's quarterly profit tumbles, but tops Wall Street estimates
January 31, 2012
J.K. WallPatent expirations on Gemzar and Zyprexa contributed to the 27-percent earnings decline, but CEO John Lechleiter touted better-than-expected
sales of other products.
MorePurdue hopes center simplifies commercialization
January 30, 2012
J.K. WallPurdue University's new Innovation and Commercialization Center is supposed to be a one-stop shop for professors to get help
developing their research into products and for outside investors to find out what research is taking place there.
MoreEli Lilly unit plans to buy feed-enzyme maker
January 24, 2012
Associated PressDrugmaker Eli Lilly and Co.'s Elanco animal health division plans to buy a privately held maker of feed-enzyme products
that improve poultry, egg and meat production.
MoreIndianapolis-area mergers and acquisitions in 2011
January 21, 2012
A number of acquisitions last year disclosed no sale price. In the Indianapolis area, those deals ranged from MacAllister
Machinery's purchase of a Caterpillar dealership in Michigan to Herff Jones' acquisition of a Memphis, Tenn.-headquartered
maker of cheerleading uniforms.
MoreCity set to cancel tax abatement for medical device firm
January 18, 2012
Polymer Technology Systems said in 2007 that it would make a $3 million investment at its operation on Zionsville Road and
create 110 jobs.
MoreAt long last, Roche wins approval of Nano
January 16, 2012
J.K. WallThe OK for a new blood glucose monitor comes more than two years after FDA officials declined to approve a previous version
of the Nano, which in rare cases generated inflated blood sugar readings because it did not distinguish properly between the
sugars glucose and maltose.
MoreIndiana's medical device workforce will need skills upgrade
January 14, 2012
J.K. WallA new report by BioCrossroads says 53 percent of the 20,000 jobs in Indiana’s medical-device sector require no more
than a high school education.
MoreNational life sciences law firm opens office here
January 7, 2012
IBJ StaffNew York-based Epstein Becker Green already has clients here, including Biomet and Roche Diagnostics.
MoreEndocyte stays course despite being battered by investors
December 31, 2011
J.K. WallAfter spending most of 2011 as a Wall Street darling, the year ended ugly for Endocyte Inc. But CEO Ron Ellis thinks the West
Lafayette-based drug developer is in better position than ever.
MoreFiling: Roche considered leaving Indy
December 27, 2011
J.K. WallIt’s hard to believe now, but as recently as two years ago, Indianapolis was close to losing its 15th-largest employer.
Roche Diagnostics Corp. was looking seriously at moving its 2,900-employee North American headquarters out of Indianapolis.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Three Magi
Cats out of the bag. The object of the game is to get acquired. That means the company has no idea how to grow beyond a certain point. Email is a 1990s technology. I have laughed at this company since day one. Such a small bit player. If it was anywhere but here, it wouldn't be newsworthy.
Esther, Indy has passed Chicago in the local government corruption arena. Don't downgrade us. We're No. 1 in the Midwest.
Does the buyer get to keep the recent Accu-Chek J.D. Power award? Be careful, those Swiss cannot be trusted. Last June they pimped Mayor Ballard and former Governor Daniels at a media op, announcing plans to invest "$300 million at its Indianapolis headquarters, creating up to 100 new jobs by 2017," only to turn around and close the Roche Nutley, NJ facility and eliminate 1000 jobs there later the same week. It seems that healthcare can be innovated only as long as money is to be made. Right now Roche seems to have big eyes for China: there are many Chinese in China and potential billions in Swiss francs! Since Roche is having difficulty with US insurance companies swallowing the bill for overpriced cancer drugs (with debatable efficacy) why not sell insurance to the Chinese and market the drugs to them there? There is a name for these sort of business practices however proper decorum precludes it use in this forum.
Same kind of Luddites who oppose I-69. Guessing their 501(c)(4) application probably sailed right through the IRS.